Comparing BioMarin Pharmaceutical (BMRN) and Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics (NASDAQ: KOOL) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.


This table compares Cesca Therapeutics and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cesca Therapeutics -65.09% -28.32% -18.90%
BioMarin Pharmaceutical -12.45% -4.60% -3.09%

Volatility & Risk

Cesca Therapeutics has a beta of -0.87, suggesting that its share price is 187% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.

Insider and Institutional Ownership

3.0% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 99.0% of BioMarin Pharmaceutical shares are held by institutional investors. 3.9% of Cesca Therapeutics shares are held by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cesca Therapeutics and BioMarin Pharmaceutical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cesca Therapeutics 0 1 0 0 2.00
BioMarin Pharmaceutical 0 5 15 1 2.81

BioMarin Pharmaceutical has a consensus target price of $114.63, indicating a potential upside of 27.06%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Cesca Therapeutics.

Earnings & Valuation

This table compares Cesca Therapeutics and BioMarin Pharmaceutical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cesca Therapeutics $14.52 million 2.16 -$29.09 million ($0.81) -3.88
BioMarin Pharmaceutical $1.12 billion 14.19 -$630.21 million ($0.90) -100.24

Cesca Therapeutics has higher earnings, but lower revenue than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Cesca Therapeutics, indicating that it is currently the more affordable of the two stocks.


BioMarin Pharmaceutical beats Cesca Therapeutics on 11 of the 14 factors compared between the two stocks.

About Cesca Therapeutics

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply